These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30286050)

  • 1. Rs4938723 Polymorphism Is Associated with Susceptibility to Hepatocellular Carcinoma Risk and Is a Protective Factor in Leukemia, Colorectal, and Esophageal Cancer.
    Xu B; Zhu Y; Tang Y; Zhang Z; Wen Q
    Med Sci Monit; 2018 Oct; 24():7057-7071. PubMed ID: 30286050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between miR-34b/c rs4938723 polymorphism and risk of cancer: An updated meta-analysis of 27 case-control studies.
    Hashemi M; Moazeni-Roodi A; Bahari G; Taheri M; Ghavami S
    J Cell Biochem; 2019 Mar; 120(3):3306-3314. PubMed ID: 30203457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association of MiR-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis.
    Liang TJ; Liu HJ; Zhao XQ; Yu CH; Li CS
    PLoS One; 2013; 8(7):e68588. PubMed ID: 23935875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic association between pri-miR-34b/c polymorphism (rs4938723 T > C) and susceptibility to cancers: evidence from published studies.
    Li X; Wang L; Yu J; Xu J; Du J
    Tumour Biol; 2014 Dec; 35(12):12525-34. PubMed ID: 25190019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk.
    Li H; Diao S; Li J; Ma B; Yuan S
    Oncotarget; 2017 Apr; 8(17):28888-28896. PubMed ID: 28415817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma.
    Xu Y; Liu L; Liu J; Zhang Y; Zhu J; Chen J; Liu S; Liu Z; Shi H; Shen H; Hu Z
    Int J Cancer; 2011 Jan; 128(2):412-7. PubMed ID: 20309940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk.
    Han Y; Pu R; Han X; Zhao J; Zhang Y; Zhang Q; Yin J; Xie J; Shen Q; Deng Y; Ding Y; Li W; Li J; Zhang H; Cao G
    PLoS One; 2013; 8(3):e58564. PubMed ID: 23516510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma.
    Chen LL; Shen Y; Zhang JB; Wang S; Jiang T; Zheng MQ; Zheng ZJ; Chen CX
    Genet Mol Res; 2016 Oct; 15(4):. PubMed ID: 27808368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population.
    Yin J; Wang X; Zheng L; Shi Y; Wang L; Shao A; Tang W; Ding G; Liu C; Liu R; Chen S; Gu H
    PLoS One; 2013; 8(11):e80570. PubMed ID: 24260422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations.
    Zhang J; Huang X; Xiao J; Yang Y; Zhou Y; Wang X; Liu Q; Yang J; Wang M; Qiu L; Zheng Y; Zhang P; Li J; Wang Y; Wei Q; Jin L; Wang J; Wang M
    PLoS One; 2014; 9(6):e100055. PubMed ID: 24945256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of TP53 rs1042522 C>G and miR-34b/c rs4938723 T>C polymorphisms with hepatoblastoma susceptibility: A seven-center case-control study.
    Liu P; Zhuo ZJ; Zhu J; Yang Z; Xin Y; Li S; Li L; Li Y; Wang H; He J
    J Gene Med; 2020 Jul; 22(7):e3182. PubMed ID: 32166848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pri-miR-34b/c rs4938723 Polymorphism Contributes to Coronary Artery Disease Susceptibility.
    Cen J; Xiong Q; Yang X; Guo J; Xiong XD; Zhang A
    Arch Med Res; 2019 May; 50(4):170-174. PubMed ID: 31499476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data.
    Yi DH; Wang BG; Zhong XP; Liu H; Liu YF
    Tumour Biol; 2014 Dec; 35(12):11967-75. PubMed ID: 25201061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.
    Liu T; Zuo L; Li L; Yin L; Liang K; Yu H; Ren H; Zhou W; Jing H; Liu Y; Kong C
    Tumour Biol; 2014 Nov; 35(11):10911-8. PubMed ID: 25085585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. rs3746444 polymorphism and susceptibility to hepatocellular carcinoma: evidence from published studies.
    Liu F; Lin H; Cheng Y; Yang L; Liu Y
    Cell Biochem Biophys; 2014 Dec; 70(3):1957-61. PubMed ID: 25074528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls.
    Tao T; Chen S; Xu B; Liu C; Wang Y; Huang Y; Chen M
    Chin J Cancer Res; 2014 Jun; 26(3):315-22. PubMed ID: 25035659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pri-miR-34b/c rs4938723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children.
    Tong N; Chu H; Wang M; Xue Y; Du M; Lu L; Zhang H; Wang F; Fang Y; Li J; Wu D; Zhang Z; Sheng X
    Leuk Lymphoma; 2016; 57(6):1436-41. PubMed ID: 26380954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-34b/c rs4938723 Polymorphism Significantly Decreases the Risk of Digestive Tract Cancer: Meta-analysis.
    Ji TX; Zhi C; Guo XG; Zhou Q; Wang GQ; Chen B; Ma FF
    Asian Pac J Cancer Prev; 2015; 16(14):6099-104. PubMed ID: 26320502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer.
    Hashemi M; Danesh H; Bizhani F; Narouie B; Sotoudeh M; Nouralizadeh A; Sharifiaghdas F; Bahari G; Taheri M
    Cancer Biomark; 2017; 18(2):155-159. PubMed ID: 27983526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk.
    Yuan F; Sun R; Chen P; Liang Y; Ni S; Quan Y; Huang J; Zhang L; Gao L
    Tumour Biol; 2016 May; 37(5):6267-73. PubMed ID: 26619844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.